ERBB4可以选择性地放大TGF-β的转移前反应
Peihong Luo1, Huanyu Hong1, Baoling Zhang1
1MOE Key Laboratory of Biosystems Homeostasis & Protection, and Zhejiang Provincial Key Laboratory of Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China; Center for Life Sciences, Shaoxing Institute, Zhejiang University, Shaoxing, Zhejiang 321000, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Cell reports
|January 24, 2025
概括
通过选择性地激活转化生长因子β (TGF-β) 信号,ERBB4促进癌症转移. 这涉及ERBB4酸化SMAD4,增强其DNA结合的转移性基因转录.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 细胞信号传递 细胞信号传递
背景情况:
- 转化生长因子β (TGF-β) 在癌症中表现出双重作用,同时作为瘤抑制剂和转移促进剂.
- 确切的分子机制决定TGF-β在瘤发生中的对立功能尚未完全理解.
- 了解这些机制对于开发向癌症疗法至关重要.
研究的目的:
- 阐明TGF-β在癌症进展中引起独特反应的特定机制.
- 确定参与TGF-β介导的转移前转移信号的关键分子参与者.
- 研究ERBB4在调节TGF-β对瘤生长和转移的影响中的作用.
主要方法:
- 通过生物化学测试,研究了ERBB4和SMAD4之间的相互作用.
- 在Tyr162.2.上分析了SMAD4的酸化状态.
- 评估了ERBB4介导的SMAD4化对TGF-β诱导的基因表达的影响,与表皮细胞转化为介质细胞转化 (EMT),细胞迁移和侵入有关.
- 利用小鼠模型评估ERBB4-SMAD4轴在肺癌转移中的作用.
主要成果:
- ERBB4选择性地促进TGF-β的转移前作用,独立于其抑制生长的功能.
- 在Tyr162中,ERBB4直接化SMAD4,增强其DNA结合能力.
- 这种酸化增强了TGF-β诱导的驱动EMT,迁移和入侵的基因转录,在体内促进肺癌转移.
结论:
- ERBB4作为TGF-β的转移前信号通路的特定调解者.
- ERBB4-SMAD4相互作用代表了一种控制瘤转移的新型调节轴.
- 准ERBB4-SMAD4通路可能是抑制癌症传播的治疗策略.
相关概念视频
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K


